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after hwrt 1rMspkntatio0 to 
amss any comlptiao with h-mpknt rejection. This cytoklne 
pm& shotdd document the rektlve activstioo of nmnwuckar 
ceu sub.setS ritbbl tbz graft. 
Ba&wmd. Up to 60% 4 mnnwmcteav &IS insltntlng the 
rudir at&aft dorbu r+ctlon are macmpbws, but thti rate 
8mi Ihe tn htmaw the in viva activatioa oi rawma* cell 
sub&s by measwi~ coiwwy sinus cytokbiv kvets atIer beart 
tlw&a&ltku 
Cellular elements within ao allogratt actively involved in 
rejection express interleukin (IL)_2 receptors and secrete 
interleukins and other cytokines into surrounding tissues and 
sentto. Measoremeot of serom interleukins aad soluble or 
cellular interleukin receptors after transplantation have been 
metabe&e nfwterbt wzests macmdwe sdiv&awitbbItJx 
used as a noainvasive marker of& rejection inatt&ort to 
quantitate immaae activation. Immuoologic markers cur- 
rentlv under investiaatioi as ooteatial rejection txedictors 
in&e mononucka;ceU number aott sub& fmc;l both the 
oeiiuheral blwd and oraao effioent (I). sdubk (2) and 
;eU;lar(3) lL-2 recepto&tede”kio-2_2(4) and IL-6$J. The 
measurement of peripheral bk+d soluble IL-2 receptor lev- 
els as a marker of rejection has been restricted by a lack of 
sensaivlty and speciticity, pwticukuly daring active iofec- 
tlon (2J.6). 
In addition to their use as clinical tools, oteasuremeot of 
cytokine levels from &graft e!?tluent may provide fix&- 
mental insights into the impxtaoce of the various cellular 
elements in the rejection process. The relative role of T 
lymphocytes may he assessed by measuring their interleukin 
products, that is, IL2 and IL2 receptors. The activation of 
two distinct T helper lymphocyte subsets may be assessed 
on the basis of differences in cytokine profile. IL-2 and 
interferon-gamma re produced by the T helper-l cell and 
IL-4. IL-5 and IL.6 are produced by a subclass designated T
helper-2 cells (7,8). The presence and activity of the IL-+- 
omducine T heloer-2 stGxlone in human transolant recid- . . 
ents rem& undetermined. Monocyteslmacrophages are im- 
portant in rejection as antigen-presenting cells and release 
monokines such as tumor necrosis factor-alpha IL-6 and 
neopterin. Neopterin is released only by acttvated macm- 
phages, usually secondary to the influence of interferon- 
gamma released from activated T lymphocytes (9) and is 
therefore specific for macrophage activation. 
0~ study war undertaken to assess the activity of cell 
subsets &in the cardiac allogmft after transplant&on and 
to explore the relation between such cellular activity and 
rejection. The concentrations of IL-2, IL-2 receptors, 1L4, 
IL-6, tumor necrosis factor-alpha and neopterln were deter- 
mined in tlte coronary sinus, which receives 75% of the 
vetto~s drainage from the myocardium. Levels were corn- 
pared with those obtained from the superiorvenacava at the 
time of routine myocardial biopsy after heart transplanta- 
tion. The levels obtained were compared with the grade of 
rejection in endomyocardial biopsy samples taken at the 
same time. 
We were able to identify macmpbage activation within 
the &graft because of release of its specific cytokine 
neopterin. This activation was confirmed by elevated corn-- 
nary sinus concentrations ofIL-6 and tumor necrosis factor- 
alpha. The T lymphocyte activation was evident with ele- 
vated soluble IL2 receptor levels in the coronary sinus; IL2 
production within the graft was not seen. The presence of T 
helper-2 lymphocyte activity within the graft was suggested 
by elevated coronary sinus levels of IL.4. We were unable to 
document any consistent elevation in the cytokine profile 
that correlated with rejection severity. 
Methods 
Sampliog procedures and assays. Under a protocol ap 
proved by the Research With Human Subjects Review 
Board on January IS, 1990 and after written, informed 
consent was obtained from each patient, paired coronary 
sinus and superior vena cave blood samples were taken at 
the time of85 routine myccardial biopsy procedures. From 
these samples, 40 were selected for batch analysis from 
patients monitored through an episode of rejection of vary- 
ing severity during which serial sampling had been per- 
formed. A total of 10 patients were represented by this 
sample. All patients were maintained on a triple in&w. 
suppressive regimen of cycloswritte, prednisone and aza. 
thioprine. Four patients were~ cruited during the initial 
posttransplantation phase and were receiving rabbit antithy 
mocyte serum as induction therapy for the 1st 7 to 10 days. 
At least two studies were availab!e for all patients, one at 
baseline and one during an episode of rejection. In two 
patients, 10 serial studies were performed at weekly inter- 
vals. Two patients had rejection >6 months after transplan- 
tation; one had a rejection episode >2 years after transplan- 
tation and the other received antithymocyte globulin for 
severe persistent rejection 6 months after transplantation. 
With use of an internal iunular aonroach. a 7F muitbur- __ . . 
pose catheter and long-znglsd biopsy sheath (Cordis) were 
advanced into the coronary sinus under tluoroscopic guid- 
ance. The catheter was zdvanced to the level of midcomnary 
sinus to minimize r&x of right atrial blood. Injection of 
contrast medium confirmed catheter position, and cinean- 
giography was undertaken to aid localization of the coronary 
sinus at subsequent studies. In this position, 50 ml of blood 
was collected. The catheter was then withdrawn to the 
superior vetta cava and an additional SO ml of blood was 
collected. Six routine right ventricular endamyocardial hi- 
opsy samples were then taken and assessed by a pathologist 
who bad no knowledge of the results of the coronary sinus 
sampling. Serum was frozen at -2VC until batch analysis. 
Concentretions of IL2, IL2 receptor, II_++, tttmm necrosis 
factor-alpha and IL.5 were assayed by usleg an enzymelinked 
immunosortent assay @LISA, T Cell Sciences) and neopterin 
was assayed by ladioimmunoessay (IO). Rejection &s as 
sessed with the standardized criteria oftbe lntemational Soci- 
etyforHeart.Transplantation(ll),andthepresenceorabsence 
of rejxtion was considered with regad to need for treatment. 
StallstkaI anaIy?es. We hypothesized that if cytokines 
were being pmduced within the ellogmft, there should be a 
significant dilference in cytokine concentration measured 
from the coronary sinus compared with that obtained during 
simultaneous sampling from the superior vena can. How- 
ever, because recirculation of the cytokine may, intluence 
the concentration at either site, tlte simultaneous estimations 
were regarded as dependent variables. Hence, a paired I test 
was used to campare coronary sinus with superiorvenacava 
cytokine concentrations in each patient, with significance 
defined as p < 0.05. 
We further hypothesized that the cytokine concentration 
measured in the coronary sinus or superior vena cave or the 
difference between these two concentrations (as a measure 
of organ-specific release of cytokine) may show a correlation 
with the severity of reje&n as determined on myocwdial 
biopsy. We compared the cytokitte concentrations measured 
in the absence of rejection with those measured during an 
episode of rejection in each patient. To allow for variations 
in cytokine concentrations within a patient over time, a 
repeated measures analysis of variance was used, with 
significance defined as p < 0.05. 
ReSUltS 
Successful entry and sampling of coronary sinus blood 
occurred in 85 of 93 attempts. No immediate or delayed 
complications were seen. 
Figure 1. There is z lack of xlat~u between coronary sinus and 
superior veuacaw.lSVC) interkukiu-2 levels and rejection severity 
as seen iiumm serial studies in seven patients. (Note the logarithmic 
SC&.) 
Cylukiie activity levels iu the cownary sinus and superior 
vettacava. The results oicytokine activity determiuations in 
both the superior veua cava and the coronary sinus are 
shown in Table I. No IL-2 activity was detectable in either 
the coronary sinus v superior vena cave in patients receiv- 
ing immunosuppressive therapy. There was no significant 
dilference belween coronary sinus and superior vena cava 
levels. The presence of rejection on biopsy did not correlate 
with a signilicattt increase in either corunary sinus or supe- 
rior vetta cuvu IL-2 levels (Fig. 1). 
Soluble IL-2 rece~br levels were similar in the curunary 
sinus (1,283 U/ml) -and superior vcna cava (1,232 Uitni) 
(<4SO U/ml are found in nomtul volunleers). The four 
patients on antithymwyte serum therapy had IL-2 receptor 
levels of 1,857 t 784 U/mi in the ccwnary sinus and 1,956 2 
888 U/ml in the superior veua caw. Those patients not 
receiving antithymucyte therapy had IL-2 receptur levels of 
541 + 176 U/ml in the curonarv sinus and levels of 535 + 
197 U/ml in the superior Vena c& (p < O.CilO5 vs. anrithy- 
mocyte therapy). There was no correlation ‘,etween cure- 
nary sinus or sup&r vena cava IL-i receptor levels and 
rejection severity. 
Inrerleukin-4 activity is siguiticantly elevated in the cow 
nary sinus compared with petiphenl levels (229 vs. 61 pe/ml. 
p = O.tMOI) (Table I). Activity was not suppressed in any 
patient during induction or maintenance immunosuppres- 
sion. In no paired sample was the peripheral IL-4 level 
elevated compared with that in the coronary sinus (Fig. 2). 
We could find no relation between IL-4 levels and rejection 
severity, althaugb there remained a consistent gradient 
between curunary sinus and peripheral IL-4 levels (Fig. 3). 
lnferleukind aaivity in the cornnary sinus (200 pgiml) 
was signdicantly greater than venous activity (I20 pglml, p = 
0.05). In only 5 of 40 samples was the txtipheral IL-6 activity 
higher than that seen in the cur&ry &us (Fig. 4). Nb 
coi-relatiuc with the presence of rejection could be found for 
lL.5. 
Levels of mmor necrosis factor-alphn werehigher in the 
curunary sinus than in the superior vena cava (68 vs. I7 
pgM. p = O.MMZ). In no instance was the peripheral !evs: 
higher than the caronary shuts level (Fig. 5). In 12 of 40 
samples, tumor necrosis factor-alpha was nut detected in the 
peripheral sample. but ME seen in the coronaty sinus 
Figure 3. The lack of correlation between interleuldn-4 activity in 
the coronary +w and superior Rena cava WC) and biopsy grade 
of rejection are <how in eight patients with serial studies. 
OL 
No Rqectlo” i?e,cct*on 
superior “ena cava Coronary Sinus 
Figure 4. Paired coronary sinus and superior vena cava mterleu- 
kin-6 estimations showing elevated coronary sinus activity (p = 
0.05). 
sample. No correlation with rejection severity was found 
(Fig. 6). 
Macrophage-specijk meraholite neopterin levels were 
higher in the coronary sinus than in peripheral blood 0.5 vs. 
2.2 nmol, p = 0.1) (Table I). In only 2 of 40 samples was the 
corotwy sinus neopteritt concentration significantly lower 
than the peripheral level. No correlation to rejection severity 
was observed. 
In one patient from wham samples were available from 
two serial episodes of rejection, there was a Z-week delay in 
biopsy evidence of rejection after elevated coronary sinus 
IL-6 levels in one episode and a I-week delay for evidence of 
Fiire 5. Paired c~rmwy sinus and superior vena cava samples 
showing consistent elevations of caranaty sinus tumor necrosis 
factor.alpha (TNF-a) (p = O.tMO2). 
No Rejection Rejection 
Qu10 6. Cornnary sinus and superior vena cava WC) tumor 
new& factor-alpha ft?We) activity showing no relation to rejec- 
tion severity in seven patients with serial data. 
a second episode of moderate rejection occunittg 4 weeks 
later (Fig. 7). 
Discussion 
Coronary sinus sampling provides cardiac-specific ve- 
nous &tent. This technique has proved useful in a?.sessittg 
myocardial metabolic and sympathetic activity. This study 
represents the first assessment of human in viva allograft 
venous etliuent sampling cd cytokines to document immune 
activation within the transplanted heat. The concentration 
gradient between coronary sinus and peripheral blood 
should correlate with local cvtoldne production but till be 
influenced by I) penetration f&t the interstitial space to the 
vascular space (spillover); 2) coronary blood Row; and 3) the 
serum clearance of the measured cytokine. Coronary sinus 
sampling was undertaken before biopsy to prevent &licial 
elevations in cyiokines as a result of the mechanical trauma 
oi‘the biopsy procedure. Care was taken to obtain samples -11 
Table 1. Venous and Coronary Sinus Cytakines Atler Heart 
Transplantation: Results From 40 Samples Taken at the Time of 
Endomvoeardial Bioosv 
the level of the midcoronary sinus to avoid dilution of the 
sample with refluxing blood from the right atrium. 
Ability of comw sinus samvline to m&m site of 
cytokine~&duetioo. in this study,.thebotential of coronary 
sinus sampling to confirm the site of cytokine production 
was established. For example, in I2 of 40 Faired tumor 
necrosis factor-alpha samples, venous activity was undetect- 
able, whereas activity in the coronary sinus measured IO to 
110 pg/ml. Revious studies 1.2) have been unable to find a 
relation between venous tumor necrosis factor-alpha levels 
and cardiac rejection. Similarly, specificity for a cardiac 
source of the cytokines is improved by considering the 
coronary sinus-superior vena cwa gradient. .4ll 28 estima- 
tions with elevated ~enotts tumor necrosis factor-alpha lev- 
els had a positive coronary sinus-superior vena cow gradi- 
ent, indicating a cardiac source. 
Lynmhwte aetivatiott in cardiac alla-&s. In the sam- 
ples &s&l, coronary sinus sampling v&s unable to detect 
IL-2 activity, despite immune activation as shown by ele- 
vated IL-2 receptor levels. There was no clear evidence of 
IL-2 or IL-2 receptor production within the graft, although a 
long half-life of the soluble receptor in serum may account 
for the lack of a gradient between the coronary sinus and 
superior vena cave. The mean serum concentration of 1,323 
U/ml is similar to previously published data (6). Tk< inability 
to establish a significant elevation in soluble Il_2 receptor 
levels above baseline with an episode of rejection may be 
explained by patients in our study who were undergoing 
therapy with antilymphocyte preparations. which are known 
to cause significant baseline elevations in semm IL-2 recep- 
tor (13). 
Interleokin-6 is produced in the allogmft, as evidenced by 
sisnificantly higher coronary sinus concentrations. This pro- 
duction may represent activation of two cell types already 
known to be present: macrophages with simultaneous pro 
duction of tumor necrosis factor-alpha and neopterin, or T 
helper-2 cells with production of IL-4 Other potential 
swrccs of IL-6 include endothelial cells in the vessel wlvall. 
which are a major interlace for im=iine xti%ty lt4). !n:e:- 
&kin 6 is nonspecific it indicating cell activation. The time 
course of cytokine production seen in the patient described 
in Figure 7 is compatible with macropnage aetivarion ccur- 
ring before lymphocyte activation and biopsy ewdence of 
rejection This may be important in predicting very early 
stage5 of immune activation, but a larger ez3o of patients 
would be required to establish the time course of cbronay 
sim s production. Interleukin.6 has been labeled as an “im- 
mune hormone” because of its ability to cxure distant 
effect:. such as fever, inducuon of acute phase proteins and 
induction oi B cell tiierentiation (IS). This syndrome is 
typical of symptomatic acute rejection. Long-term elevation 
of IL-6 lwels in mic: has teen associated with the dcvelog 
ment of B cell neoplasias (161, raising the possibility that 
!ong-term elevation of lL-6 may be responsible for lympho- 
mas after transplantation. Preliminary evidence (17) suggests 
that lonc-teno elevation of IL-6 may be associated with the 
development of transplant atheroscierosis in the graft. 
The specific elevations of coronary sinus IL.4 strongly 
suggest the presence of the T helper-2 lymphocyte subset 
within the graft. and this report independently conlinos 
preliminary evidew for the presence and activafion of this 
T lymphocyte sububset in human transplant recipients. In 
murine models this T helper subset was not suppressed by 
conventional immunosuppressive therapy (18). a tinding 
confirmed by the elevated levels in the coronary sinus in OUT 
WJW of patients receivircz such theraw. Elevated IL-4 
&<s do not correlate with rejection, bit a more complex 
relation should be sought. There is recent evidence that IL-4 
may have an immunomodulating effect and that antibodies to 
IL-4 can omduce acme reiection in rat allamafts fBallioe SF. 
perronalcomm”nicatio”,-0etober l!Bo). - ” 
Cells of the monoeytelmacmphage class constitute 3WG to 
M)% of graft-intiltrating cells as detected by immuno- 
fluorescence in an autopsy study (19) of hearts explanted for 
Mminant rejection. The preseoxe of macrophage activation 
in lesser degrees of rejection has been suggested by the 
presence of its major cytokine tumor necrosis factor-alpha in 
both serum (20) and tissue (16.21). There are alternate 
sources of small amounts of tomor necrosis factor-alpha (22) 
and therefore production of tomor necrosis factor-alpha does 
not indicate specific mononuclear subset activation. 
Serum levels of neopterin were measot-ed in both the 
coronary sinus and superior vena eava because neopterin is 
produced only by activated macrophages (23). The elevation 
of coronary sinus neopterin levels compared with superior 
vena cwa concentrations ccmfmns macrophage activation 
within the graft and suggests that macrophages may also be 
the source of the tumor necrosis factor-alpha and IL-6. The 
long half-life of neapteiin in serum (70 to 200 rain), partico- 
My in patients with renal impairment (23). may explain the 
elevated superior vena cow concentrations and lack of a 
more significant gradient between the coronary sinus and 
superior “ena cam. 
The significance of long-term macrophage activatiat BS 
seen in patients weeks to months after transplantation is 
unclear. A complex relation with macmphage activation 
modulating or preceding rejection is suggested by the cyto- 
kine profile in one patient (Fii. 7) and remains to be 
confirmed. Elevations in serum neopterin (24) and IL-6 (5) 
have been shown to prxede biopsy evidewe of rejection by 
up to 3 days. Coronary sinus sampling should allow the in 
viva assessment of interactions among cytokines. In vitro 
and in mice, IL-5 has been shown to inhibit the formation of 
tumor necrosis factor-alpha (7.5); this did not appearto be the 
case in our patients because tumor necrosis factor-alpha 
levels were elevated in the coronary sinus in all patients. 
Tumor necrosis factor-alpha is a known potent inducer of 
IL6 (26): this effect may predominate because simultaneous 
elevations of both cytokines were seen in our series. In vitro, 
the production of tumor necrosis factor-alpha is inhibited by 
corticostemid therapy but not by cyclosporine (27). This was 
not apparent in our patients. who were all receiving triple 
immunosuppressive therapy. 
The patients included in this study were selected from a 
larger group because of the presence of a rejection episode 
early or late in the course of transplantation. It is possible 
that elevations of IL-4 or IL-6, even in the absence of 
concurrent biopsy rejection, may identify a group of patients 
with a greater level of baseline immune activation who are at 
increased risk for recurrent rejection. 
Canclwions. Coronary sinus sampling of cytokines LW- 
vides the ability to mea&e graft- aid c&p&it% im&ne 
activation. It allows the site of production of cvtokines to be 
established, confirms the p&nce and activ&on of macro- 
phases within a cardiac allograft and suggests the presence 
and activity of the T helper-2 subset within the graft. It 
provides independent confirmation for the production of 
cytokines within the graft, as suggested by cytokine gene 
transcription studies in biopsy material (28). Further study of 
immune activation markers from organ efAuent should pro- 
vide insights into clinical immunobiology, mechanisms of 
graft rejection and in viva assessment of immunosuppressive 
repimens. 
